United States

ENDO 2021

T3 Enters Axon Terminals of Mouse Cortical Neurons, Is Retrogradely Transported to the Cell Nucleus and Activates Gene Expression

ENDO is the leading meeting for endocrinology research and clinical care worldwide. 

technical paper

The Worldwide Landscape of Variants in the Androgen Receptor Gene Related to the Androgen Insensitivity Syndrome: An Integrative Analysis

Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER+) breast cancer. Disseminated ER+ tumor cells can remain viable but quiescent for years to decades. Contributing factors to metastatic spread include the maintenance and expansion of breast cancer stem cells (CSCs). Breast CSCs are poorly proliferative and frequently exist as a minority population in therapy resistant tumors. Our objective is to define novel signaling pathways that govern therapy resistance in ER+ breast cancer. In this study, we show that cytoplasmic complexes composed of steroid receptor (SR) co-activators, PELP1 and SRC-3, modulate breast CSC expansion through upregulation of the HIF-activated metabolic target genes PFKFB3 and PFKFB4. Seahorse metabolic assays demonstrated that cytoplasmic PELP1 influences cellular metabolism by increasing both glycolysis and mitochondrial respiration. PELP1 interacts with PFKFB3 and PFKFB4 proteins, and inhibition of PFKFB3 and PFKFB4 kinase activity blocks PELP1-induced tumorspheres and protein-protein interactions with SRC-3. PFKFB4 knockdown inhibited in vivo emergence of circulating tumor cell (CTC) populations in ER+ mammary intraductal (MIND) xenografts. Application of PFKFB inhibitors in combination with ER targeted therapies blocked tumorsphere formation in multiple models of advanced breast cancer, including tamoxifen (TamR) and paclitaxel (TaxR) resistant models and ER+ patient-derived organoids (PDxO). Together, our data suggest that PELP1, SRC-3, and PFKFBs cooperate to drive ER+ tumor cells that include CSCs and CTCs. Identifying non-ER pharmacological targets offers a useful approach to blocking metastatic escape from standard of care ER/estrogen (E2)-targeted strategies to overcome endocrine and chemotherapy resistance in ER+ breast cancer.?? 

Steroid Receptor Co-Activators Regulate Metabolic Kinases to Drive Therapy Resistant ER+ Breast Cancer

Prohibitn-1 Transgenic Mice Revealed an Important Role of Prohibitin in Testicular Steroidogenesis

Diabetes Mellitus What Has Changed in the Past 30 Years?

Advances in Monitoring and Delivering InsulinMeters, CGM, Pens, Pumps, Inhaled Transplantation

Clinical Research 101

A (Brief) Introduction to Drug Regulation Before, During, (and Soon) After COVID

Adult Growth Hormone Deficiency: The Ups and Downs

The 'Up' Side of Growth Hormone

Endocrine Nurses Society Position Statement on Transgender and Gender-Diverse Care

https://d3smihljt9218e.cloudfront.net/transcript/25866/subtitle/edce638d491763b0addbdec3b9b3bdd0.vtt

English (automatic)

Premium content

T3 Enters Axon Terminals of Mouse Cortical Neurons, Is Retrogradely Transported to the Cell Nucleus and Activates Gene Expression

Downloads

Next from ENDO 2021

The Worldwide Landscape of Variants in the Androgen Receptor Gene Related to the Androgen Insensitivity Syndrome: An Integrative Analysis

Similar lecture

Biophysical Model of GnRH Neuronal Activity and Secretion

Stay up to date with the latest Underline news!

PRESENTATIONS

CONFERENCES

COMPANY

RESOURCES